CN103260644A - 含有狂犬病毒抗原的副痘病毒载体 - Google Patents
含有狂犬病毒抗原的副痘病毒载体 Download PDFInfo
- Publication number
- CN103260644A CN103260644A CN2011800357117A CN201180035711A CN103260644A CN 103260644 A CN103260644 A CN 103260644A CN 2011800357117 A CN2011800357117 A CN 2011800357117A CN 201180035711 A CN201180035711 A CN 201180035711A CN 103260644 A CN103260644 A CN 103260644A
- Authority
- CN
- China
- Prior art keywords
- parapoxvirus
- virus
- reorganization
- animal
- heterologous dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24241—Use of virus, viral particle or viral elements as a vector
- C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Description
Claims (22)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34698810P | 2010-05-21 | 2010-05-21 | |
US61/346,988 | 2010-05-21 | ||
US41428710P | 2010-11-16 | 2010-11-16 | |
US61/414,287 | 2010-11-16 | ||
PCT/IB2011/051847 WO2011145013A1 (en) | 2010-05-21 | 2011-04-27 | Parapoxvirus vectors containing rabies virus antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103260644A true CN103260644A (zh) | 2013-08-21 |
Family
ID=44972661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800357117A Pending CN103260644A (zh) | 2010-05-21 | 2011-04-27 | 含有狂犬病毒抗原的副痘病毒载体 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20110287051A1 (zh) |
EP (1) | EP2571521A1 (zh) |
JP (1) | JP5890399B2 (zh) |
KR (2) | KR20130008645A (zh) |
CN (1) | CN103260644A (zh) |
AR (1) | AR081409A1 (zh) |
AU (1) | AU2011254315B2 (zh) |
BR (1) | BR112012029633A8 (zh) |
CA (1) | CA2798055C (zh) |
CL (1) | CL2012003219A1 (zh) |
CO (1) | CO6670515A2 (zh) |
MX (1) | MX338052B (zh) |
NZ (1) | NZ603431A (zh) |
RU (1) | RU2545694C2 (zh) |
UY (1) | UY33400A (zh) |
WO (1) | WO2011145013A1 (zh) |
ZA (1) | ZA201208264B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111944769A (zh) * | 2020-08-10 | 2020-11-17 | 塔里木大学 | 一种狂犬病毒g蛋白-羊痘病毒重组疫苗的构建方法 |
WO2022033573A1 (zh) * | 2020-08-13 | 2022-02-17 | 苏州般若生物科技有限公司 | 一种突变型羊传染性脓疱皮炎病毒及其用途 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102014116334A1 (de) * | 2014-11-10 | 2016-05-12 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Herstellung von rekombinanten Expressionsvektoren |
DE102015111756A1 (de) * | 2015-07-20 | 2017-01-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Rekombinanter Orf-Virus-Vektor |
US11013798B2 (en) * | 2016-03-21 | 2021-05-25 | South Dakota Board Of Regents | Orf virus-based platform for vaccine delivery |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217027A (zh) * | 1996-02-28 | 1999-05-19 | 拜尔公司 | 含外源dna的副痘病毒,其制备及其在疫苗中的应用 |
US6844000B2 (en) * | 2001-12-07 | 2005-01-18 | Bayer Pharmaceuticals Corporation | Use of Parapox B2L protein to treat cancer and modify immune responses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
EP0237686A1 (en) * | 1986-03-18 | 1987-09-23 | Institut Pasteur | DNA sequences derived from the rabies virus genome |
DK1418942T3 (da) | 2001-12-10 | 2005-11-28 | Bavarian Nordic As | Poxvirus-holdige sammensætninger og fremgangsmåde til fremstilling deraf |
AU2008363648B9 (en) * | 2008-10-31 | 2013-08-22 | Tremrx, Inc. | Vaccination with poxvirus vectors via mechanical epidermal disruption |
-
2011
- 2011-04-27 BR BR112012029633A patent/BR112012029633A8/pt not_active IP Right Cessation
- 2011-04-27 EP EP11722560A patent/EP2571521A1/en not_active Withdrawn
- 2011-04-27 MX MX2012013451A patent/MX338052B/es active IP Right Grant
- 2011-04-27 KR KR1020127032744A patent/KR20130008645A/ko active Application Filing
- 2011-04-27 WO PCT/IB2011/051847 patent/WO2011145013A1/en active Application Filing
- 2011-04-27 RU RU2012149036/10A patent/RU2545694C2/ru not_active IP Right Cessation
- 2011-04-27 AU AU2011254315A patent/AU2011254315B2/en not_active Ceased
- 2011-04-27 CA CA2798055A patent/CA2798055C/en not_active Expired - Fee Related
- 2011-04-27 JP JP2013511758A patent/JP5890399B2/ja not_active Expired - Fee Related
- 2011-04-27 NZ NZ603431A patent/NZ603431A/en not_active IP Right Cessation
- 2011-04-27 CN CN2011800357117A patent/CN103260644A/zh active Pending
- 2011-04-27 KR KR1020157001619A patent/KR20150015551A/ko not_active Application Discontinuation
- 2011-05-19 US US13/111,020 patent/US20110287051A1/en not_active Abandoned
- 2011-05-20 AR ARP110101750A patent/AR081409A1/es unknown
- 2011-05-23 UY UY0001033400A patent/UY33400A/es not_active Application Discontinuation
-
2012
- 2012-11-02 ZA ZA2012/08264A patent/ZA201208264B/en unknown
- 2012-11-19 CL CL2012003219A patent/CL2012003219A1/es unknown
- 2012-11-21 CO CO12210839A patent/CO6670515A2/es not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217027A (zh) * | 1996-02-28 | 1999-05-19 | 拜尔公司 | 含外源dna的副痘病毒,其制备及其在疫苗中的应用 |
US6844000B2 (en) * | 2001-12-07 | 2005-01-18 | Bayer Pharmaceuticals Corporation | Use of Parapox B2L protein to treat cancer and modify immune responses |
Non-Patent Citations (2)
Title |
---|
ALEJANDRO BRUNA ET AL.: "Antigen delivery systems for veterinary vaccine development Viral-vector based delivery systems", 《VACCINE》 * |
张德礼等: "狂犬病疫苗研究进展评述", 《医药导报》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111944769A (zh) * | 2020-08-10 | 2020-11-17 | 塔里木大学 | 一种狂犬病毒g蛋白-羊痘病毒重组疫苗的构建方法 |
CN111944769B (zh) * | 2020-08-10 | 2022-06-28 | 塔里木大学 | 一种狂犬病毒g蛋白-羊痘病毒重组疫苗的构建方法 |
WO2022033573A1 (zh) * | 2020-08-13 | 2022-02-17 | 苏州般若生物科技有限公司 | 一种突变型羊传染性脓疱皮炎病毒及其用途 |
Also Published As
Publication number | Publication date |
---|---|
AR081409A1 (es) | 2012-08-29 |
US20110287051A1 (en) | 2011-11-24 |
RU2012149036A (ru) | 2014-06-27 |
RU2545694C2 (ru) | 2015-04-10 |
ZA201208264B (en) | 2014-01-29 |
EP2571521A1 (en) | 2013-03-27 |
MX2012013451A (es) | 2013-01-22 |
CO6670515A2 (es) | 2013-05-15 |
CA2798055A1 (en) | 2011-11-24 |
BR112012029633A8 (pt) | 2017-12-05 |
CL2012003219A1 (es) | 2013-04-05 |
CA2798055C (en) | 2015-11-24 |
UY33400A (es) | 2011-12-30 |
AU2011254315B2 (en) | 2015-05-14 |
AU2011254315A1 (en) | 2013-01-10 |
KR20130008645A (ko) | 2013-01-22 |
WO2011145013A1 (en) | 2011-11-24 |
JP5890399B2 (ja) | 2016-03-22 |
NZ603431A (en) | 2014-06-27 |
BR112012029633A2 (pt) | 2016-09-20 |
JP2013535953A (ja) | 2013-09-19 |
KR20150015551A (ko) | 2015-02-10 |
MX338052B (es) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2658439C2 (ru) | Мультивалентные рекомбинантные вирусы птичьего герпеса и вакцины для иммунизации птиц | |
CN103260644A (zh) | 含有狂犬病毒抗原的副痘病毒载体 | |
CN103079593A (zh) | 副痘病毒载体 | |
CN113943714A (zh) | 一种猫杯状病毒毒株及其应用 | |
Williams et al. | A recombinant bovine herpesvirus-4 vectored vaccine delivered via intranasal nebulization elicits viral neutralizing antibody titers in cattle | |
Ronchi et al. | Preliminary results on innocuity and immunogenicity of an inactivated vaccine against Peste des petits ruminants. | |
RU2697151C2 (ru) | Рекомбинантный нокаутный мутант вируса нодулярного дерматита и его применение | |
US20230149528A1 (en) | Development of mosaic vaccines against foot and mouth disease virus serotype o | |
ES2593965T3 (es) | Vacuna marcadora contra la peste porcina clásica | |
US10196616B2 (en) | Altered avian virus for in-ovo inoculation and methods of use thereof | |
JP4856939B2 (ja) | 感染症予防ワクチン | |
CN104689343A (zh) | 治疗性结核分枝杆菌dna疫苗及其制备方法与应用 | |
AU2014262215B2 (en) | Porcine Torque teno virus vaccines and diagnosis | |
CN117778334A (zh) | 表达猪瘟病毒e2蛋白的重组猪伪狂犬病毒株及其制备方法和应用 | |
Li et al. | Flt3 ligand enhanced the immunogenicity of classical swine fever vectored vaccine based on human adenovirus by fusing to the E2 glycoprotein | |
Singh et al. | A single dose of naked DNA expressing E2 protein is capable of providing full protection against CSFV | |
Li HeLin et al. | Flt3 ligand enhanced the immunogenicity of classical swine fever vectored vaccine based on human adenovirus by fusing to the E2 glycoprotein. | |
Rajib Deb et al. | Application of marker vaccines against livestock diseases. | |
OA19861A (en) | Recombinant lumpy skin disease virus knock-out mutant and uses thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1184046 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160323 Address after: New jersey, USA Applicant after: Zoetis Services LLC Address before: New jersey, USA Applicant before: ZOETIS LLC |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130821 |
|
RJ01 | Rejection of invention patent application after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1184046 Country of ref document: HK |